Theravance Biopharma (TBPH) Deferred Taxes (2024 - 2026)

Theravance Biopharma (TBPH) has reported Deferred Taxes for 3 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Deferred Taxes fell 61.93% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$12.7 million (down 42.12% YoY), while the FY2025 annual figure was -$11.5 million, down 52.11% from the prior year.
• Deferred Taxes slipped to -$3.0 million in Q1 2026 per TBPH's latest filing, from $30000.0 in the prior quarter.
• Across five years, Deferred Taxes topped out at $994000.0 in Q3 2025 and bottomed at -$10.7 million in Q2 2025.
• Historically, Deferred Taxes has averaged -$2.5 million across 3 years, with a median of -$561000.0 in 2024.
• On a YoY basis, Deferred Taxes climbed as much as 1004.44% in 2025 and fell as far as 1805.7% in 2025.
• Theravance Biopharma's Deferred Taxes stood at -$6.6 million in 2024, then soared by 100.46% to $30000.0 in 2025, then slumped by 10096.67% to -$3.0 million in 2026.
• Business Quant data shows TBPH's Deferred Taxes at -$3.0 million in Q1 2026, $30000.0 in Q4 2025, and $994000.0 in Q3 2025.